Literature DB >> 11401007

Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine.

S G Holtzman1.   

Abstract

RATIONALE: Inhibitors of neuronal dopamine uptake, such as GBR 12909, decrease IV cocaine self-administration by laboratory animals and have been proposed as potential therapeutic agents for abuse of psychomotor stimulant drugs.
OBJECTIVES: This study was performed to determine how GBR 12909 alters the discriminative stimulus effects of methamphetamine and cocaine.
METHODS: Rats were trained to discriminate between IP injections of 10 mg/kg cocaine and saline and were tested for stimulus generalization to cocaine, GBR 12909, and methamphetamine. Based upon the ED50 of the individual drugs, combinations of GBR 12909 and either cocaine or methamphetamine were tested that comprised a) 1 part GBR 12909 and 2 parts cocaine or methamphetamine, or b) 2 parts GBR 12909 and 1 part cocaine or methamphetamine.
RESULTS: GBR 12909 and cocaine were equipotent and 30-fold less potent than methamphetamine in producing cocaine-like discriminative effects. GBR 12909 and cocaine produced cocaine-like discriminative effects synergistically in the ratio of 1 part GBR 12909:2 parts cocaine (0.16+0.32 to 1.92+ 3.87 mg/kg) and nearly synergistically in the ratio of 2 parts GBR 12909:1 part cocaine (0.32+0.16 to 3.92+ 1.91 mg/kg). GBR 12909 and methamphetamine (0.32+0.02 to 3.20+0.22 mg/kg or 0.65+0.01 to 6.53+0.1 mg/kg) were simply additive in both sets of fixed-ratio dose combinations.
CONCLUSIONS: The synergy of GBR 12909 and cocaine and the additivity of GBR 12909 and methamphetamine run counter to the presumed mechanisms of action of these drugs at dopamine nerve terminals, which might have implications for the use of GBR 12909 in the treatment of addiction to cocaine or amphetamines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401007     DOI: 10.1007/s002130100684

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Monoaminergic psychomotor stimulants: discriminative stimulus effects and dopamine efflux.

Authors:  Rajeev I Desai; Carol A Paronis; Jared Martin; Ramya Desai; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-02-26       Impact factor: 4.030

2.  Intra-VTA CART 55-102 reduces the locomotor effect of systemic cocaine in rats: an isobolographic analysis.

Authors:  Jason N Jaworski; Heather L Kimmel; Darlene A Mitrano; Ronald J Tallarida; Michael J Kuhar
Journal:  Neuropeptides       Date:  2007-02-07       Impact factor: 3.286

3.  Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans.

Authors:  Rajkumar J Sevak; William W Stoops; Lon R Hays; Craig R Rush
Journal:  J Pharmacol Exp Ther       Date:  2008-12-22       Impact factor: 4.030

4.  Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity.

Authors:  Gianluigi Tanda; Amy Hauck Newman; Aaron L Ebbs; Valeria Tronci; Jennifer L Green; Ronald J Tallarida; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-05-29       Impact factor: 4.030

Review 5.  Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.

Authors:  Zheng-Xiong Xi; Eliot L Gardner
Journal:  Curr Drug Abuse Rev       Date:  2008-11

6.  2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations.

Authors:  Weimin C Hong; Theresa A Kopajtic; Lifen Xu; Stacey A Lomenzo; Bernandie Jean; Jeffry D Madura; Christopher K Surratt; Mark L Trudell; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2016-01-14       Impact factor: 4.030

Review 7.  Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations.

Authors:  Sally L Huskinson; Jennifer E Naylor; James K Rowlett; Kevin B Freeman
Journal:  Neuropharmacology       Date:  2014-03-22       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.